These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 27574944)

  • 21. Quality-adjusted time without symptoms or toxicity analysis of pazopanib versus sunitinib in patients with renal cell carcinoma.
    Beaumont JL; Salsman JM; Diaz J; Deen KC; McCann L; Powles T; Hackshaw MD; Motzer RJ; Cella D
    Cancer; 2016 Apr; 122(7):1108-15. PubMed ID: 27000445
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pazopanib induced unilateral posterior reversible encephalopathy syndrome.
    Arslan BM; Bajrami A; Demir E; Cabalar M; Yayla V
    Ideggyogy Sz; 2017 Mar; 70(3-4):140-144. PubMed ID: 29870619
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Benefits of pazopanib over sunitinib for renal cell carcinoma.
    Granovetter M
    Lancet Oncol; 2016 Mar; 17(3):e93. PubMed ID: 26853821
    [No Abstract]   [Full Text] [Related]  

  • 24. An open-label extension study to evaluate safety and efficacy of pazopanib in patients with advanced renal cell carcinoma.
    Sternberg CN; Davis ID; Deen KC; Sigal E; Hawkins RE
    Oncology; 2014; 87(6):342-50. PubMed ID: 25227656
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pazopanib does not bring remarkable improvement in patients with angiosarcoma.
    Kitamura S; Yanagi T; Inamura Y; Hata H; Imafuku K; Yoshino K; Shimizu H
    J Dermatol; 2017 Jan; 44(1):64-67. PubMed ID: 27569550
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pazopanib- and bevacizumab-induced reversible heart failure in a patient with metastatic renal cell carcinoma: A case report.
    Abdallah AO; Vallurupalli S; Kunthur A
    J Oncol Pharm Pract; 2016 Jun; 22(3):561-5. PubMed ID: 25956420
    [No Abstract]   [Full Text] [Related]  

  • 27. Intimal Sarcoma of the Pulmonary Artery Treated with Pazopanib.
    Funatsu Y; Hirayama M; Shiraishi J; Asakura T; Wakaki M; Yamada E; Fujimoto K; Satomi R; Inaki S; Murata Y; Oyamada Y
    Intern Med; 2016; 55(16):2197-202. PubMed ID: 27522994
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Is change in blood pressure a biomarker of pazopanib and sunitinib efficacy in advanced/metastatic renal cell carcinoma?
    Goldstein D; Rosenberg JE; Figlin RA; Townsend RR; McCann L; Carpenter C; Pandite L
    Eur J Cancer; 2016 Jan; 53():96-104. PubMed ID: 26702763
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Pazopanib for treatment of renal cell carcinoma and soft tissue sarcomas].
    Brotelle T; Bay JO
    Bull Cancer; 2014 Jun; 101(6):641-6. PubMed ID: 24977453
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Response to pazopanib in two pediatric patients with pretreated relapsing synovial sarcoma.
    Casanova M; Basso E; Magni C; Bergamaschi L; Chiaravalli S; Carta R; Tirtei E; Massimino M; Fagioli F; Ferrari A
    Tumori; 2017 Jan; 103(1):e1-e3. PubMed ID: 27647230
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Guillain-Barré syndrome in a patient with renal cell carcinoma following the first course of pazopanib therapy.
    Koshikawa H; Tsukie T; Kurita A; Fujikura M; Suzuki M; Araki K
    J Infect Chemother; 2017 Nov; 23(11):798-799. PubMed ID: 28506529
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pazopanib treatment slows progression and stabilizes disease in patients with taxane-resistant cutaneous angiosarcoma.
    Ogata D; Yanagisawa H; Suzuki K; Oashi K; Yamazaki N; Tsuchida T
    Med Oncol; 2016 Oct; 33(10):116. PubMed ID: 27613162
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pazopanib: Clinical development of a potent anti-angiogenic drug.
    Schutz FA; Choueiri TK; Sternberg CN
    Crit Rev Oncol Hematol; 2011 Mar; 77(3):163-71. PubMed ID: 20456972
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Outcomes of patients with metastatic renal cell carcinoma treated with pazopanib in daily clinical practice: a single institution experience.
    Ricotta R; Di Bella S
    Tumori; 2014; 100(3):e87-91. PubMed ID: 25076258
    [TBL] [Abstract][Full Text] [Related]  

  • 35. First-Line and Sequential Use of Pazopanib Followed by Mammalian Target of Rapamycin Inhibitor Therapy Among Patients With Advanced Renal Cell Carcinoma in a US Community Oncology Setting.
    Vogelzang NJ; Hackshaw MD; Hutson TE; Bhowmik D; Yap M; Rembert D; Jonasch E
    Clin Genitourin Cancer; 2015 Jun; 13(3):210-7. PubMed ID: 25498215
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pazopanib in advanced vascular sarcomas: an EORTC Soft Tissue and Bone Sarcoma Group (STBSG) retrospective analysis.
    Kollár A; Jones RL; Stacchiotti S; Gelderblom H; Guida M; Grignani G; Steeghs N; Safwat A; Katz D; Duffaud F; Sleijfer S; van der Graaf WT; Touati N; Litière S; Marreaud S; Gronchi A; Kasper B
    Acta Oncol; 2017 Jan; 56(1):88-92. PubMed ID: 27838944
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Spontaneous enterocutaneous and rectovaginal fistula: potential complications during therapy with anti-angiogenic drugs in renal cancer].
    Valverde-Martínez S; Ramírez-Backhaus M; Rubio-Briones J; Climent-Durán MÁ; Iborra I; Solsona-Narbón E
    Arch Esp Urol; 2015 Mar; 68(2):187-90. PubMed ID: 25774827
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Refractory metastasis of cutaneous angiosarcoma showing complete response to pazopanib.
    Fujiwara S; Nagai H; Nakamachi Y; Kawano S; Nishigori C
    Eur J Dermatol; 2015; 25(1):71-3. PubMed ID: 25679339
    [No Abstract]   [Full Text] [Related]  

  • 39. Effects of ketoconazole and esomeprazole on the pharmacokinetics of pazopanib in patients with solid tumors.
    Tan AR; Gibbon DG; Stein MN; Lindquist D; Edenfield JW; Martin JC; Gregory C; Suttle AB; Tada H; Botbyl J; Stephenson JJ
    Cancer Chemother Pharmacol; 2013 Jun; 71(6):1635-43. PubMed ID: 23636448
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Incidence and risk of hypertension with pazopanib in patients with cancer: a meta-analysis.
    Qi WX; Lin F; Sun YJ; Tang LN; He AN; Yao Y; Shen Z
    Cancer Chemother Pharmacol; 2013 Feb; 71(2):431-9. PubMed ID: 23178953
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.